Using 2019 EULAR/ACR criteria to predict organ damage in lupus patients
The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus Patients
Sohag University · NCT06313151
This study is trying to see if a new set of guidelines can help doctors predict organ damage and future health outcomes in people with lupus.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 16 Years to 60 Years |
| Sex | All |
| Sponsor | Sohag University (other) |
| Drugs / interventions | cyclophosphamide |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06313151 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine if the 2019 EULAR/ACR classification criteria can effectively assess organ damage and predict prognosis in patients with systemic lupus erythematosus (SLE). The study will enroll 200 SLE patients attending the Rheumatology Department at Sohag University Hospital from March 2024 to March 2025. Participants will be randomly selected and undergo comprehensive evaluations, including demographic data collection, clinical assessments, and laboratory tests to analyze disease activity and organ involvement.
Who should consider this trial
Good fit: Ideal candidates are patients aged 16 and older who have been diagnosed with SLE according to the 2019 ACR/EULAR criteria and have a disease duration of more than six months.
Not a fit: Patients with drug-induced lupus or those with overlap syndromes such as systemic sclerosis or dermatomyositis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict organ damage in SLE patients, leading to better management and treatment strategies.
How similar studies have performed: While the use of classification criteria in predicting outcomes is common, this specific application of the 2019 EULAR/ACR criteria in SLE is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient age is above 16 years old 2. Patient is classified as SLE patient according to 2019 ACR/EULAR classification criteria 3. patient with disease duration more than 6 month. Exclusion Criteria: 1. Patient with drug-induced lupus and those with systemic sclerosis or dermatomyositis overlap syndromes . 2. patient with disease duration less than 6 month will be excluded.
Where this trial is running
Sohag
- Sohag University — Sohag, Egypt (RECRUITING)
Study contacts
- Study coordinator: alyaa A mohamed, doctorate
- Email: aliaa.abdelhameed@med.sohag.edu.eg
- Phone: 01007218644
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: SLE, and Organ Damage Index